

EIS Eligible.

Zilico Ltd **seeks** a further £500k growth funding via Deepbridge Syndicate



www.deepbridgesyndicate.com



Sector:
Healthcare

Stage:
Established - existing revenue, pre-profit

Location:
North-West

Roles available:
Not Hiring

Zilico Limited has developed an innovative and patented cancer diagnostic device technology that will improve and extend current cancer screening programmes by providing accurate and objective results real-time.

The initial focus of the Company is cervical cancer and oral cancer, with over 13m coloscopies performed in mature markets, and a further 30m in emerging BRIC markets – equating to a target market size of \$700m for Zedscan.

The Company's device, Zedscan, examines the electrical impedance properties of tissues through electrical resistance analysis and measurement. Different organs have characteristic electrical impedances, and research has shown that it is possible to predict the impedance of different tissues once you know enough about their structure, resulting in knowledge of the impedance spectrum characteristic to a particular tissue. The Company's technology provides an objective method to differentiate between normal, precancerous, and cancerous cells. This provides a real-time diagnosis that removes subjectivity and potentially avoids the need for a biopsy.

Zedscan is already routinely in use in Royal Stoke University Hospital, County Hospital Stafford, St Mary's Manchester and Hallamshire Hospital, Sheffield.

Key Milestones

- 2013 CE Marking awarded under EU legislation
- 2013 Awarded BioNow Product of the Year
- 2014 Winner of 2014 Medilink National Award for Partnership with NHS
- 2014 'Highly Commended' - 2014 UK NHS Excellence in Supply Awards, NW Region.
- 2014 Regulatory approvals received in Australia, Canada and Israel
- 2015 NICE publishes Medtech Innovation Briefing
- 2015 First hospital in Gulf Cooperation Council States adopt Zedscan
- 2016 Finalist in HSJ "Improving Care with Technology" award category
- 2016 Selected by the IFC, a member of the World Bank Group, to be part of the inaugural TechEmerge program, to conduct pilots across India

Use of Investment

This current £500,000 fundraise by experienced investment manager Deepbridge Capital, is part of a £4m total raise, and will be used to take the Company through the next development phase, including:

- Driving sales of ZedScan in the EU and the rest of the world
- Launch of the APX200 screening technology
- Funding further clinical trials to achieve registration with the US Food and Drug Administration

How to Invest

You can invest alongside Deepbridge via their online investment platform Deepbridge Syndicate

To see more about the opportunity and to invest, please visit: <https://deepbridge-syndicate.encystry.com/deals/1274>



For more information, please contact:

Fuchsia Curry on fuchsia.curry@deepbridgecapital.com or call 07766 954 155

The value of investments can go down as well as up, so you could get back less than or none of your invested capital. This opportunity may not be suitable or appropriate for your personal circumstances. The levels and basis of taxation may change and depends on your individual circumstances. The marketability of this type of investment is often restricted and you may have difficulty selling at any price. If you are in any doubt, you should consult a suitably qualified financial advisor.

This Financial Promotion is approved for the purposes of the Financial Services and Markets Act 2000 by Sturgeon Ventures LLP, which is authorised and regulated by the Financial Services Authority (FRN 452811). None of the underlying company's activities, finances or documentation have been reviewed or verified by Sturgeon Ventures LLP, nor has it conducted due diligence on any of its Principals or Directors. An investment into the underlying company is not covered by the Financial Services Compensation Scheme.